Bigtincan Holdings Limited

Equities

BTH

AU000000BTH6

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 10:04:36 2024-06-02 pm EDT			5-day change	1st Jan Change
0.145 ^AUD	+3.57%		-3.33%	-27.50%

Apr. 11	Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19%	MT
Mar. 18	Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index	CI

Bigtincan Holdings Limited Provides Earnings Guidance for the Fiscal Year 2023

August 29, 2022 at 06:22 pm EDT

Bigtincan Holdings Limited provided earnings guidance for the fiscal year 2023. For the year, the company expected annualised Recurring Revenue in the range of $137 million to $143 million and revenue in the range of $123 million to 128 million.

Latest news about Bigtincan Holdings Limited

Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19%	Apr. 10	MT
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index	Mar. 17	CI
Bigtincan Shares Shed 11% as Fiscal H1 Revenue Contracts 1.5%; Loss Narrows	Feb. 27	MT
Transcript : Bigtincan Holdings Limited, H1 2024 Earnings Call, Feb 27, 2024	Feb. 27
Bigtincan Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Transcript : Bigtincan Holdings Limited - Shareholder/Analyst Call	Nov. 28
Bigtincan Holdings Limited Provides Earnings Guidance for the Fiscal Year 2024	Nov. 14	CI
Bigtincan Holdings Limited Announces Resignation of Farouk Hussein as Non-Executive Director	23-10-02	CI
Bigtincan Holdings Limited(ASX:BTH) dropped from S&P Global BMI Index	23-09-18	CI
Bigtincan Reportedly Say It Remains in Takeover Talks	23-09-17	CI
Bigtincan Holdings Launches Cost Reduction Program	23-09-15	MT
Transcript : Bigtincan Holdings Limited, 2023 Earnings Call, Aug 30, 2023	23-08-30
Bigtincan Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Bigtincan to Borrow AU$15 Million to Grow AI Technology	23-07-21	MT
Bigtincan Holdings Limited Provides Financial Results Outlook for Fiscal Year 2023	23-07-20	CI
Transcript : Bigtincan Holdings Limited - Special Call	23-05-21
Bigtincan Holdings Limited Launches GenieAI Technology, Delivering Transformational Sales Productivity Gains to Customers	23-03-12	CI
Bigtincan Holdings Limited Provides Earnings Guidance for the Year 2023	23-03-12	CI
Transcript : Bigtincan Holdings Limited, H1 2023 Earnings Call, Feb 27, 2023	23-02-26
Bigtincan Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Bigtincan Appoints Morgan Stanley to Evaluate Interest it Received from Potential Buyers	23-01-16	CI
Bigtincan Acquires Revenue Data Capture Platform SalesDirector.ai	22-12-27	MT
Bigtincan's New Relationship Intelligence Technology Unlocks Value Hidden in Relationship Networks	22-12-12	CI
Bigtincan Holdings to Seek M&A	22-12-08	CI
Bigtincan completes capital raising despite suitor SQN Investors' concerns	22-12-07	RE

Chart Bigtincan Holdings Limited

Duration

Period

More charts

Company Profile

Beta Pharmaceutical Limited is a Australia-based biopharmaceutical company. The Company is focused on the identification, development and commercialization of products and therapies targeting the chemoprevention and treatment of breast cancer. The Company is working in collaboration with scientists at the College of Pharmacy, University of Louisiana at Monroe in southern the United States of America (ULM) to develop cancer chemopreventive agents using natural phytonutrients, called tocotrienols as treatments for breast cancers. Funded by Beta Pharmaceutical Limited, the applied research programme with ULM includes four laboratories and is known as the Breast Cancer and Health Project, which has been underway.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bigtincan Holdings Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.14 AUD

Average target price

0.39 AUD

Spread / Average Target

+178.57%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIGTINCAN HOLDINGS LIMITED	-27.50%	57.28M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research